Endocrine Abstracts (2019) 65 P416 | DOI: 10.1530/endoabs.65.P416

Outcomes of Liraglutide as treatment for weight regain after bariatric surgery: A 2-year retrospective study

Majid Alameri, Asma Alnuaimi & Tarek Fiad


Department of Endocrinology at Sheikh Khalifa Medical City, Abu Dhabi, UAE


Introduction: Limited data is available on Liraglutide as a treatment option for weight regain after bariatric surgery. We aim to report the efficacy of Liraglutide as a treatment for weight regain in UAE population who underwent bariatric surgery.

Methods: Retrospective analysis was performed on all patients with weight regain after bariatric surgery who received Liraglutide (dose range 0.6 up to 3.0 mg/day) while attending bariatric clinic of Sheikh Khalifa Medical City (AD, UAE) over two years from 2017 to 2019.

Results: 56 patients who received Liraglutide for weight regain after bariatric surgery during the study period were identified. 49 patients were included for final analysis as 7 patients stopped Liraglutide (5 due to severe nausea and vomiting and 2 due to pregnancy). Mean age was 37.9±9.1 years and majority of patients were female (81.6%). 59.2% had Laparoscopic sleeve gastrectomy (LSG n=29), 36.7% had laparoscopic Roux-en-Y gastric bypass (LRYGB, n=18) and 4.1% had Laparoscopic gastric banding (n=2). Mean presurgical weight was 123.2 ±17.8 kg and mean BMI was 58.4±10.2 kg/m2. Mean minimal body mass index after surgical intervention was 33.5±5.1 kg/m2 and mean weight was 85.7±12.9 kg. Mean weight at Liraglutide initiation was 95.1±13.3 kg and mean BMI of 36.9±4.4 kg/m2. After 3 months, mean weight and BMI reduction were 5.4±9.8 kg and 1.3±1.1 kg/m2 respectively (P<0.01).

Conclusion: Liraglutide can be considered as a safe and effective adjunctive treatment for weight regain after bariatric surgery. Further studies are required to identify clinical predictors that could affect the response to Liraglutide in these patients.

Article tools

My recent searches

No recent searches.